Lisata Therapeutics 将来の成長
Future 基準チェック /06
Lisata Therapeuticsの収益は年間5.4%で減少すると予測されていますが、年間収益は年間127.8%で増加すると予想されています。EPS は年間20.8%で増加すると予想されています。
主要情報
-5.4%
収益成長率
20.81%
EPS成長率
| Biotechs 収益成長 | 25.4% |
| 収益成長率 | 127.8% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 17 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 01
LSTA: Kuva Deal Uncertainty Will Ultimately Support Higher Future Earnings Potential
Analysts have reduced their fair value estimate for Lisata Therapeutics from $9.50 to $4.00, citing increased uncertainty around the Kuva Labs takeover financing and the risk that the deal may not close. What's in the News Lisata Therapeutics filed its 10-K on March 12, 2026, covering the period ending December 31, 2025.ナラティブの更新 • May 02
LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk
Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.
ナラティブの更新 • Apr 17
LSTA: Kuva Cash Deal Will Support Future Upside Potential
Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.ナラティブの更新 • Apr 03
LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential
Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.ナラティブの更新 • Mar 20
LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations
Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.ナラティブの更新 • Mar 05
LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside
Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.ナラティブの更新 • Feb 18
LSTA: Pending Kuva Acquisition And Contingent Rights Will Support Future Upside
Analysts have reduced their price target on Lisata Therapeutics from $13.00 to approximately $11.33. They cited updated assumptions around fair value, discount rate, long-term revenue growth, profit margins, and future P/E multiples following recent changes in research coverage.ナラティブの更新 • Feb 04
LSTA: Acquisition Offer And Downgrade Reset Expectations Before Potential Upside
Analysts have trimmed their price target on Lisata Therapeutics from US$15 to US$15.00, reflecting updated assumptions around revenue growth, profit margins, discount rates, and a higher future P/E multiple following recent research, including a downgrade from Brookline. Analyst Commentary Despite the recent trim in the headline price target, bullish analysts still see room for upside if Lisata executes on its plans and delivers against current expectations.ナラティブの更新 • Jan 21
LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade
Analysts have slightly reduced their fair value estimate to US$13.00, citing modest adjustments to the discount rate, long term profit margin expectations, and a lower implied future P/E as they reassess Lisata Therapeutics following a recent downgrade in Street research. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$13.00 fair value as still reflecting upside potential, provided that execution on key clinical and operational milestones tracks internal expectations.ナラティブの更新 • Jan 07
LSTA: Improved Profitability Assumptions Will Support Strong Future Upside Potential
Analysts have modestly lifted their price target for Lisata Therapeutics, citing slightly improved profit margin assumptions at 16.24% and a lower future P/E estimate of 103.37x as key drivers of their updated valuation. Valuation Changes Fair Value: Remains unchanged at 13.0, suggesting the overall valuation anchor has been kept steady.ナラティブの更新 • Dec 24
LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares
Analysts have reduced their price target on Lisata Therapeutics from 32.00 dollars to 15.00 dollars, citing higher discount rates despite stronger projected revenue growth, improved profit margins, and a materially lower future price-to-earnings multiple. What's in the News Lisata Therapeutics and Catalent signed a global product license agreement granting Catalent non exclusive worldwide rights to incorporate certepetide into antibody drug conjugates using its SMARTag technology platform, including the ability to partner with third parties (Key Developments) Under the Catalent collaboration, Lisata is eligible for more than 10 million dollars in tiered study initiation milestone payments plus revenue sharing on future product sales and partnerships (Key Developments) Certepetide, Lisata's proprietary iRGD cyclic peptide, has shown favorable safety, tolerability, and clinical activity in trials aimed at improving the effectiveness of standard of care chemotherapy for pancreatic cancer and other solid tumors (Key Developments) Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., Orphan Drug Designation for glioma and osteosarcoma in the U.S., and Rare Pediatric Disease Designation for osteosarcoma in the U.S. (Key Developments) Preliminary data from the PDAC cohort of the Phase 1/2a CENDIFOX trial of certepetide plus FOLFIRINOX based therapies will be presented at the AACR Special Conference in Cancer Research on Advances in Pancreatic Cancer Research on September 29, 2025, in Boston, Massachusetts (Key Developments) Valuation Changes Fair Value Estimate: Reduced significantly from 32 dollars to 15 dollars per share, reflecting a more conservative assessment despite stronger fundamentals.ナラティブの更新 • Dec 09
LSTA: Upcoming Cancer Trial Milestones Will Drive Strong Upside Potential
Analysts have nudged their price target on Lisata Therapeutics slightly higher to 13.00 dollars from 13.00 dollars, reflecting modest adjustments to the discount rate and long-term valuation assumptions, despite largely unchanged growth and margin expectations. What's in the News Lisata Therapeutics and Catalent entered a global product license agreement granting Catalent worldwide, non exclusive rights to use certepetide in antibody drug conjugates developed on its SMARTag platform, with Lisata eligible for over 10 million dollars in tiered milestone payments plus revenue sharing on future sales and partnerships (Key Developments) Certepetide, Lisata's proprietary internalizing RGD cyclic peptide, will be evaluated by Catalent as a payload across multiple ADCs targeting difficult to treat diseases.ナラティブの更新 • Nov 25
LSTA: Global Licensing Milestones And Trial Results Will Drive Future Upside
Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.ナラティブの更新 • Nov 09
LSTA: Milestone Payments And Clinical Progress Will Drive Future Upside
Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook. What's in the News Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform.分析記事 • Aug 13
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Apr 26
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
新しいナラティブ • Apr 14
Certepetide Advancements And Regulatory Approvals Will Set New Care Standards
Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.分析記事 • Dec 24
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 14
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders. Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST. CLBS +39.28% premarket to $0.71.Seeking Alpha • Aug 04
Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Caladrius Biosciences press release (NASDAQ:CLBS): Q2 GAAP EPS of -$0.11 beats by $0.01. As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to close in Q3.分析記事 • May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 7 | -19 | N/A | N/A | 1 |
| 12/31/2027 | N/A | -21 | N/A | N/A | 1 |
| 12/31/2026 | N/A | -18 | N/A | N/A | 1 |
| 3/31/2026 | 0 | -16 | -14 | -14 | N/A |
| 12/31/2025 | 0 | -17 | -16 | -16 | N/A |
| 9/30/2025 | 1 | -18 | -17 | -17 | N/A |
| 6/30/2025 | 1 | -19 | -16 | -16 | N/A |
| 3/31/2025 | 1 | -19 | -18 | -18 | N/A |
| 12/31/2024 | 1 | -20 | -19 | -19 | N/A |
| 9/30/2024 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -21 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -20 | -19 | -19 | N/A |
| 12/31/2023 | N/A | -21 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -21 | -22 | -22 | N/A |
| 6/30/2023 | N/A | -54 | -23 | -23 | N/A |
| 3/31/2023 | N/A | -56 | -24 | -24 | N/A |
| 12/31/2022 | N/A | -54 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -55 | -20 | -19 | N/A |
| 6/30/2022 | N/A | -25 | -21 | -20 | N/A |
| 3/31/2022 | N/A | -24 | -20 | -20 | N/A |
| 12/31/2021 | N/A | -27 | -22 | -22 | N/A |
| 9/30/2021 | N/A | -26 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -25 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -12 | -13 | -13 | N/A |
| 12/31/2020 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2020 | N/A | -7 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -19 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2019 | N/A | -18 | N/A | -18 | N/A |
| 6/30/2019 | N/A | -17 | N/A | -18 | N/A |
| 3/31/2019 | N/A | -16 | N/A | -19 | N/A |
| 12/31/2018 | N/A | -16 | N/A | -20 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -21 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -22 | N/A |
| 3/31/2018 | N/A | -14 | N/A | -17 | N/A |
| 12/31/2017 | N/A | -16 | N/A | -21 | N/A |
| 9/30/2017 | N/A | -18 | N/A | -20 | N/A |
| 6/30/2017 | N/A | -20 | N/A | -20 | N/A |
| 3/31/2017 | -7 | -26 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -31 | N/A | -24 | N/A |
| 9/30/2016 | 8 | -59 | N/A | -29 | N/A |
| 6/30/2016 | 13 | -64 | N/A | -32 | N/A |
| 3/31/2016 | 27 | -74 | N/A | -33 | N/A |
| 12/31/2015 | 22 | -81 | N/A | -39 | N/A |
| 9/30/2015 | 20 | -59 | N/A | -41 | N/A |
| 6/30/2015 | 18 | -65 | N/A | -46 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: LSTA今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: LSTA今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: LSTA今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: LSTA来年は収益がないと予測されています。
高い収益成長: LSTA来年は収益がないと予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: LSTAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/02 20:04 |
| 終値 | 2026/06/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Lisata Therapeutics, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Jan Wald | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |